Tag Archives: dacarbazine

Halaven Shows Survival Advantage in Liposarcoma – FDA Approved

Halaven (eribulin mesylate) was approved by the FDA for the treatment of patients with unresectable or advanced liposarcoma. The treatment is approved for patients who previously had undergone chemotherapy with an anthracycline drug. It was previously approved for patients with breast cancer who had undergone at least two prior chemotherapeutic regimens, including an anthracycline and a taxane. Continue reading

Nivolumab Phase 3 study stopped early for efficacy

Great news – nivolumab, BMS’ PD-1 immune checkpoint control inhibitor was shown to prolong overall survival when used front-line in patients with advanced melanoma. ┬áThe study was stopped early, that is before it fully enrolled the planned number of patients, by an independent data monitoring committee because it was shown to be quite effective. Continue reading